Sarcopedia

BenignBone

Fibrous Dysplasia

Synonyms: FD, Fibrous dysplasia of Bone

GNAS1 mutation testing is diagnostic and distinguishes from Low-grade OS or other fibro-osseous lesions

Quick Facts

Behaviour

Benign

Category

Bone

Synonyms

  • FD
  • Fibrous dysplasia of Bone

Category

Bone

Behaviour

Benign

Gender

M = F

Tissue of Origin

Bone

Epidemiology

  • Common fibro-osseous lesion
  • Peak incidence in childhood and adolescence
  • Three forms: monostotic (75%), polyostotic (25%), and McCune-Albright Syndrome

Clinical Features

  • Pain, deformity, pathological fracture
  • Limb length discrepancy in polyostotic form
  • McCune-Albright: café-au-lait spots, precocious puberty, endocrine abnormalities
  • Shepherd's crook deformity of proximal femur

Location

  • Proximal femur and skull/facial bones most common
  • Ribs (polyostotic)
  • Tibia, humerus
  • Gnathic bones (jaw)

Imaging

  • Ground-glass matrix ('smoky' appearance on X-ray/CT)
  • Shepherd's crook deformity of proximal femur
  • MRI: heterogeneous, may show cystic areas
  • Bone scan: intensely hot (polyostotic lesions demonstrate full skeletal extent)

Pathology

  • Curvilinear trabeculae of woven Bone ('Chinese characters') in Fibrous stroma
  • No osteoblastic rimming (unlike ossifying fibroma)
  • GNAS1 mutation in osteoprogenitor cells
  • Cartilaginous islands in 10% (fibrocartilaginous dysplasia)

Genetics

  • Activating GNAS1 mutation (Arg201His or Arg201Cys) - postzygotic somatic
  • Not heritable - sporadic mosaic mutation
  • Degree of mosaicism correlates with extent of disease

Treatment

  • Medical: bisphosphonates (pamidronate) for pain and to reduce fracture risk
  • Surgical: curettage and Bone grafting for impending/completed fractures
  • Intramedullary nailing for shepherd's crook deformity
  • Denosumab for refractory cases

Prognosis

  • Generally Benign - does not spontaneously resolve
  • Malignant transformation <1% (to osteosarcoma, fibrosarcoma, MFH)
  • McCune-Albright Syndrome associated with endocrine morbidity
  • Monostotic form generally stable after skeletal maturity

Key Points

  • GNAS1 mutation testing is diagnostic and distinguishes from Low-grade OS or other fibro-osseous lesions
  • Malignant transformation risk is very Low but increases with radiation exposure (avoid radiotherapy)
  • Bisphosphonates are the mainstay of non-surgical management
  • Regular screening for endocrine abnormalities in McCune-Albright

Workup - Blood Tests

  • Bone profile: ALP, calcium, phosphate - ALP elevated in polyostotic disease
  • PTH, 25-OH vitamin D - exclude hyperparathyroidism
  • GH, IGF-1 - if McCune-Albright Syndrome suspected
  • Cortisol, ACTH - Cushing association in McCune-Albright
  • Thyroid function tests - hyperthyroidism in McCune-Albright

Workup - Local Imaging

  • Plain radiograph
  • MRI - if Malignant transformation suspected (pain, rapid growth, soft tissue mass)
  • CT - cortical thinning, full extent of lesion

Workup - Biopsy

  • Biopsy NOT routinely required for classic imaging appearance
  • Core needle biopsy - if Malignant transformation suspected
  • Histology: woven Bone trabeculae ('Chinese letters') in Fibrous stroma
  • GNAS mutation (R201H/C) - present in 95%; confirms Fibrous dysplasia

Workup - Staging

  • Bone scan or whole-body MRI - polyostotic disease extent
  • Full skeletal survey for McCune-Albright workup

Workup - Other

  • Endocrinology referral for McCune-Albright Syndrome
  • Bisphosphonates (pamidronate/zoledronate) for pain and fracture risk reduction

Follow-up Summary

  1. 1

    Monostotic FD

    clinical review + plain X-ray at 6 months, then annual for 2 years; discharge if stable

  2. 2

    Polyostotic FD

    Annual clinical review + plain X-ray of affected sites; Bone scan at baseline to map extent

  3. 3

    McCune-Albright Syndrome

    Annual multidisciplinary review (endocrinology, orthopaedics, ophthalmology)

  4. 4

    No Malignant transformation surveillance required unless rapid growth or sarcomatous features suspected

  5. 5

    Bisphosphonate therapy

    monitor renal function and calcium/phosphate at each review

  6. 6

    Discharge from sarcoma service if stable, no fracture risk, and confirmed Benign FD diagnosis

Medical disclaimer

The content on Sarcopedia is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis or treatment. Always consult with a qualified physician regarding any health concerns or before starting any new treatment. Reliance on any information provided on this site is solely at your own risk.